- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Jonathan Ledermann
Cancer Research UK and UCL Cancer Institute
London, UK
Expert Jonathan Ledermann talks about limitations of chemotherapy in ovarian cancer, the nature of the disease in general as well as current research and new treatment options being investigated.
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
